Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 102 Matches

Entecavir_V15R1_USFDA_20170810
Model Files Publication
Entecavir compound file in healthy volunteers. Evaluation of the effect of renal impairment on PK of OAT substrates. NOTE: file has predicted Vss of 0.98 L/kg. Table 1 value is 0.9 L/kg. http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full
Search Score: 1
Maraviroc&Telaprevir&VRT_127394_V15R1_Pfizer_20200405
Model Files Publication
http://dmd.aspetjournals.org/content/47/5/493.long Maraviroc and Telaprevir/healthy volunteer. The workspace is set up as multiple dose over 10 days to account for the MBI of Telaprevir. The metabolite of Telaprevir (VRT-127394) is included in the workspace.
Search Score: 1
Oseltamivir_Carboxylate_V15R1_USFDA_20170810
Model Files Publication
http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full OC model updated from Hsu 2014. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: logP -2.1 in the model. different from Table 1 (-2.4).
Search Score: 1
Dihydroartemisinin (DHA)
Model Files Publication

Brand Name(s) include: D-Artepp, Artekin, Diphos, TimeQuin, Eurartesim, Duocotecxin

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

The model at-a-glance

  Absorption Model
  • First-Order

  Volume of Distribution

  • Full PBPK (Method 2)

Note: Kp scalar used

  Route of Elimination
  • UGT1A9 (50%); UGT2B7(50%)

  Perpetrator DDI
  • CYP1A2 Inhibitor

  Validation

  • Four clinical studies describing single dose exposure of DHA were used to verify the PBPK model.  100% of studies were within 2-fold, of which 75% were within 1.5-fold.  Thus, the model performance was deemed acceptable.

  Limitations
  • The model does not account for the differences in plasma fraction unbound observed in patients compared to healthy volunteers.
  • Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.

  Updates in V19
  • Updated in vitro data
    • Propranolol Papp: 30 cm/s x 106
  • Converted model to full PBPK with Vss predicted through Method 2
  • Updated retrograde clearance

 

Search Score: 1

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|